Patents
Literature
3 results about "Redox status" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The average glutathione redox status for adults through the age of 45 is about -148 mV, with the majority having values between -140 and -150 and most having values between -130 and -160. After the age of 45, the average magnitude of the redox status decreases linearly with age by about 7 mV per decade.
Use of methylene blue to treat ischemia-reperfusion injury
PCT designated stageWO2026050472A1Dead animal preservationHeterocyclic compound active ingredientsElectron donorMitochondrial redox
This method provides in situ quantification of the overall mitochondrial redox state, the redox state of individual cytochromes such as complex III and IV, and methods for treatment should the redox state be identified as hyperoxidized. Mitochondrial rescue from IRI-mediated injury can be achieved using methylene blue, which acts as an alternate electron donor to bypass complex III.
Owner:THE GENERAL HOSPITAL CORP
Composition capable of improving inflammatory aging and application thereof
The invention provides a composition for improving inflammatory aging and application thereof. The composition is formed by compounding ergothioneine and verbascoside according to the mass ratio of 1: 10-10: 1, the interaction of a binary mixture is calculated by adopting a joint index (CI) method, and the synergistic anti-inflammatory effect of ergothioneine and verbascoside is determined to relieve inflammatory aging. The composition can improve inflammation by inhibiting the levels of cell inflammatory factors IL-1beta, IL-6 and TNF-alpha; the influence on inflammation is weakened by inhibiting the antioxidant activity (ROS, MDA and GSSG) of cells. Furthermore, the composition can inhibit cell ferroptosis in a targeted manner, reduce the lipid peroxidation level and the cell ferrous iron content, reduce cell aging and maintain the redox state of cells. The composition provided by the invention has a remarkable targeted inhibition effect on cell ferroptosis, and has important significance on inhibition of senescence related to ferroptosis and product development.
Owner:ZHEJIANG UNIV +1
PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane as active ingredient and use thereof
PCT designated stageWO2026134722A1Cosmetic preparationsMetabolism disorderPharmaceutical drugBULK ACTIVE INGREDIENT
The present invention relates to a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane as an active ingredient and use thereof. More specifically, the present invention relates to: a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient; and use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition, as a composition for preventing, treating or ameliorating diseases requiring the oxidative inactivation of PTEN, and a method for detecting PTEN redox state.
Owner:LUX ANIMA CO LTD